Setting the standard for sustainability in pharma

Sustainability has become a crucial pillar in pharmaceutical development, with environmental concerns and resource management demanding immediate attention from organisations of all sizes and specialities.

Among those leading the sustainability charge is Samsung Biologics. In recent years, the contract development and manufacturing organisation (CDMO) has made considerable strides in advancing sustainability efforts around the world, becoming the first Korean company to receive the Terra Carta Seal in 2022 and most recently earning the prestigious EcoVadis platinum sustainability rating.

With over three decades of leadership experience spanning healthcare and informatics, James Choi – executive vice president, chief marketing officer, and head of sales support and global public affairs at Samsung Biologics – has been well-positioned to witness the evolution of environmental, social, and governance in the industry. To find out more about the company’s work, Deep Dive sat down with Choi to discuss the current and future landscape of sustainability.

Eloise McLennan:
Following the top 1% EcoVadis rating, how are you translating that into environmental and societal improvements?

James Choi: EcoVadis is a reflection of all the work that we put in to date. There are several that I could name. We’ve established an ESG committee on our board of directors. We did that several years ago, with independent board members to really make sure that we have solid governance in terms of ESG across all of our operations. Since then, we’ve been making a concerted effort to focus on ESG.

• Read the full article in pharmaphorum's Deep Dive digital magazine